用Ipomoea batatas提取物功能化粉生物聚合物:在II型糖尿病中提供生物活性天然系统
Brenda Avelina Lopez Muñiz1, Rosa Martha Perez Gutierrez2, Alethia Muñiz-Ramirez3
1Autonomous University of San Luis Potosí, Faculty of Chemical Sciences, Martínez 6, Dr. Manuel Nava Avenue, University Zone, Zip Code 78210, San Luis Potosí, S.L.P., Mexico.
Current drug delivery
|August 18, 2025
概括
一种基于粉的新型生物聚合物有效地提供了Ipomoea batatas提取物,显著改善了斑马鱼的2型糖尿病标志物. 这种天然化合物输送系统显示出未来治疗应用的前景.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 2型糖尿病是一种代谢障碍,以慢性高血糖症为标志.
- 天然植物化合物,如来自Ipomoea batatas的化合物,为糖尿病提供潜在的治疗益处.
研究的目的:
- 开发和评估一种以粉为基础的生物聚合物,与Ipomoea batatas提取物功能化,用于2型糖尿病治疗.
- 评估新型输送系统的物理化学特性和体内疗效.
主要方法:
- 创建了一个基于粉的生物聚合物,并加载了甲醇Ipomoea batatas提取物 (IBM).
- 分析了物理化学性质 (胀,封装,释放).
- 在糖尿病斑马鱼 (Danio rerio) 的体内研究中使用了浸泡和口服给药途径.
主要成果:
- 该生物聚合物表现出333.03%的膨胀能力和47.78%的封装效率.
- 用IBM和生物聚合物-药物合物 (BP-IBM) 治疗显著降低了斑马鱼的葡萄糖,甘油三和胆固醇水平.
- 治疗抑制了先进的糖化最终产品 (AGEs) 的形成.
结论:
- 这种基于粉的生物聚合物增强了Ipomoea batatas提取物的生物可用性和治疗效果.
- 开发的系统是一个有希望的,无毒的平台,用于为2型糖尿病管理提供生物活性化合物.
- 双重给药途径提供了灵活性,突出了该系统的治疗潜力.
相关概念视频
Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
258
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
258
Dipeptidyl Peptidase 4 Inhibitors
257
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
257
Insulin: Biosynthesis, Chemistry, and Preparation
529
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
529


